Open AccessIndications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination
Author(s) -
Bangyu Luo,
Jixi Li,
Xianhua Hou,
Qiao Yang,
Yi Zhou,
Jun Ye,
XiaoCheng Wu,
Yimei Feng,
Tianyu Hu,
Zhi Xu,
Ying He,
Jianping Sun
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-0288
Subject(s) - vaccination , medicine , covid-19 , immunosuppression , pandemic , immune system , cancer , immunology , virus , immunotherapy , disease , infectious disease (medical specialty)
The COVID-19 pandemic has lasted over 1 year and will not disappear in a short time. There is no specific remedy against the virus as yet. Vaccination is thus far one of the most important strategies for preventing COVID-19. Cancer patients with COVID-19 have a higher mortality because of immunosuppression. Immune checkpoint inhibitors (ICIs) are a novel anticancer strategy for blocking inhibitory pathways, which are related to the immune response. There is a question regarding whether COVID-19 vaccination and ICI treatment impact each other in cancer patients. This review explores both sides of the relationship between ICI treatment and COVID-19 vaccination and suggests good efficacy and safety of ICI treatment after COVID-19 vaccination as well as little impact on the virus protection and toxicity associated with COVID-19 vaccination during ICI treatment.